Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 14:13:1040024.
doi: 10.3389/fimmu.2022.1040024. eCollection 2022.

C-Reactive Protein (CRP): A poor prognostic biomarker in COVID-19

Mohamed Zakaria Bouayed  1 , Ilyass Laaribi  1 , Charaf Eddine Mohammed Chatar  1 , Iliass Benaini  1 , Mohammed Amine Bouazzaoui  2 , Younes Oujidi  1 , Samia Berrichi  1 , Ghizlane El Aidouni  1 , Houssam Bkiyar  1   3 , Naima Abda  2 , Brahim Housni  1   3
Affiliations

C-Reactive Protein (CRP): A poor prognostic biomarker in COVID-19

Mohamed Zakaria Bouayed et al. Front Immunol. .

Abstract

Introduction: The COVID-19 pandemic continues to be rampant with considerable morbidity and mortality worldwide since its emergence in December 2019. Several studies have focused on identifying different predictive factors of poor prognosis, including biological markers, such as C Reactive Protein among others. The objective of our work was to determine whether the CRP levels on admission to the intensive care unit are predictive of an unfavorable evolution of patients with COVID-19 through the experience of the Anesthesia and Intensive Care Unit of the University Hospital of Oujda and to compare our results with those reported in the literature.

Methods: We conducted a retrospective, monocentric, descriptive and analytical study in the Department of Anesthesia and Intensive Care of the Mohammed VI University Hospital of Oujda, Morocco, between March 2020 and October 2021, including all critically ill patients admitted to the department during this period and meeting the inclusion criteria. The baseline admission CRP value was arbitrarily set at 100mg/d, thus conditioning the division of our patients into two groups (group 1: CRP < 100mg/L, group 2: CRP ≥ 100mg/L).

Results: Among our 1035 included patients, 291 patients with had a CRP<100mlg/L (group 1) and 744 presented a CRP level equal or superior to 100mg/L (group 2). Lung parenchymal involvement was more severe or even critical (CT involvement > 75%) in group 2 (60.8%) compared to group 1 (39.2%). In group 2, 79.8% of patients were mechanically ventilated, compared to 20.2% of patients in group 1. Finally, the mortality rate in patients with a CRP ≥ 100mg/l was 77.4%, compared with 22.6% for patients with a CRP < 100mg/l. These findings are all statistically highly significant (p<0.001).

Conclusion: Given the high contagiousness of the virus and the emergence of several variants, the management of the COVID-19 pandemic has focused more on prevention through vaccination against the virus, but also on an early identification of patients likely to evolve unfavorably for a personalized management.

Keywords: C Reactive Protein (CRP); COVID-19; SARS-CoV-2; biomarkers; mortality; prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Receiver operating characteristic (ROC) curves of CRP for predicting the disease severity in COVID-19.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. COVID-19 dashboard by the center for systems science and engineering (CSSE). Johns Hopkins University (JHU). Available at: https://coronavirus.jhu.edu/map.html. - PMC - PubMed
    1. Treskova-Schwarzbach M, Haas L, Reda S, Pilic A, Borodova A, Karimi K, et al. . Pre-existing health conditions and severe COVID-19 outcomes: An umbrella review approach and meta-analysis of global evidence. BMC Med (2021) 19(1):212. doi: 10.1186/s12916-021-02058-6 - DOI - PMC - PubMed
    1. Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med (2020) 383(23):2255–73. doi: 10.1056/NEJMra2026131 - DOI - PMC - PubMed
    1. Battaglini D, Lopes-Pacheco M, Castro-Faria-Neto HC, Pelosi P, Rocco PRM. Laboratory biomarkers for diagnosis and prognosis in COVID-19. Front Immunol (2022) 13:857573. doi: 10.3389/fimmu.2022.857573 - DOI - PMC - PubMed
    1. van de Veerdonk FL, Giamarellos-Bourboulis E, Pickkers P, Derde L, Leavis H, van Crevel R, et al. . A guide to immunotherapy for COVID-19. Nat Med (2022) 28(1):39–50. doi: 10.1038/s41591-021-01643-9 - DOI - PubMed

Substances